Bupropion hydrochloride extended-release
Pro Research Analysisby 
Searched over 200M research papers
Bupropion Hydrochloride Extended-Release: Efficacy, Safety, and Pharmacokinetics
Efficacy in Major Depressive Disorder (MDD)
Comparative Efficacy with Escitalopram
Bupropion hydrochloride extended-release (XL) has been shown to be non-inferior to escitalopram in treating major depressive disorder (MDD) in Chinese patients. In a randomized, double-blind study involving 538 patients, the mean change in Hamilton Depression Rating Scale-17 (HAMD-17) scores at week 8 was -14.5 for the bupropion XL group compared to -15.4 for the escitalopram group. The response and remission rates were also comparable between the two groups, with bupropion XL showing a response rate of 69.6% and a remission rate of 39.7% .
Effectiveness in Atypical Depression
Bupropion XL has also demonstrated effectiveness in patients with MDD with atypical features. In an open-label, rater-blinded study, 51 patients showed a 55.3% reduction in HAM-D-29 scores from baseline to the end of treatment. The study reported that 24.4% of patients achieved remission, and 51.2% were classified as responders. Common adverse effects included headache, dry mouth, dizziness, and dyspepsia .
Safety Profile
Common Adverse Effects
The most frequently reported adverse events for bupropion XL include nausea, headache, dry mouth, dizziness, and dyspepsia. In the comparative study with escitalopram, nausea was the most common adverse event, affecting 10.5% of patients in the bupropion XL group 12.
Seizure Risk
Although bupropion is known to lower the seizure threshold, cases of grand mal seizures specifically induced by the extended-release formulation have been documented. One case involved a 27-year-old woman who experienced seizures after six months of bupropion XL therapy, highlighting the need for caution, especially in patients with a history of seizures or those taking other medications that lower the seizure threshold .
Pharmacokinetics and Formulation Considerations
Bioavailability and Metabolism
Bupropion XL is designed to provide a prolonged release of the drug, resulting in a higher concentration over an extended period. Pharmacokinetic studies indicate that the relative bioavailability of the extended-release formulations ranges from 72.3% to 78.8% compared to the immediate-release form. The drug is extensively metabolized in the liver, producing three active metabolites: hydroxybupropion, threohydrobupropion, and erythrohydrobupropion 38.
Dosage and Administration
The usual adult target dose for bupropion XL is 300 mg per day, administered as 150 mg twice daily. The dose can be increased to a maximum of 400 mg per day if no clinical improvement is observed after several weeks at the 300 mg per day dose. It is crucial to maintain an interval of at least 8 hours between doses to avoid high peak concentrations .
Conclusion
Bupropion hydrochloride extended-release is an effective and generally well-tolerated option for treating major depressive disorder, including cases with atypical features. Its efficacy is comparable to that of escitalopram, and it offers a favorable safety profile with manageable adverse effects. However, caution is advised due to the potential risk of seizures. Understanding its pharmacokinetic properties and appropriate dosing can help optimize its clinical use.
Sources and full results
Most relevant research papers on this topic